Text size
Download area
Background Information
Articles & Presentations
- Interview mit Pablo Umaña, Roche GlycArt AG, Mitarbeiterzeitung "myRoche", Ausgabe 2011/2
- Attraktives Chancen- und Risikoprofil - Was Venture Capital-Investoren an Spin-offs reizt, VentureCapital Magazin „Start-up 2010“, Hanns-Peter Wiese, Partner
- “In der Frühphase fehlen solvente Investoren”
Going Public „Biotechnologie 2009“, Oktober 2009, Dr. Holger Reithinger, Partner, Hanns-Peter Wiese, Partner - VCs Dessert Stock Market
Biotech&Finances, August 2009, Hanns-Peter Wiese, Partner - Menschen & Macher, Teil 20 der Serie: Köpfe der deutschsprachigen Private Equity-Szene
Venture Capital Magazin April 2008, Hanns-Peter Wiese - Europe’s biotech maintains momentum
Science Business, October 2007 - Biotech-Startups suchen nach Geldquellen
BÖRSE online, October 2007, Dr. Hans A. Küpper, Partner und Hanns-Peter Wiese, Partner - Die transatlantische Connection
Going Public “Biotechnologie”, September 2007, Hanns-Peter Wiese, Partner - “Venture Capital steht wieder auf der Tagesordnung”
Transkript Nr. 8-9, 2007, Interview mit Dr. Hans A. Küpper, Dr.Holger Reithinger und Hanns-Peter Wiese - “Glauben Sie noch an die deutsche Biotechnologie?“
FINANCE, September 2007, Hanns-Peter Wiese, Dr. Hans Küpper und Dr.Holger N. Reithinger - Nous avons observé des injections ciblées et messurées de capital
Biotech&Finances, September 2007, Hanns-Peter Wiese, Partner - Investment in European Biotech: Outlook and Trends
- Dr. Peter Reinisch's presentation at the 2006 Biotech in Europe Investor Forum, featuring the results of the GLSV Biotech Investment Barometer
- Herausforderung Finanzierung - Biotech Firmen in Europa. Hanns-Peter Wiese, Going Public September 2006
- The impact of biotechnology on modern healthcare and drug development
Peter Reinisch, partner of Global Life Science Ventures, argues that biotechnology will play a decisive role in the development of the healthcare sector - Privateequityonline July 2006 - After the Hype: The Horizons for Biotech
Hanns-Peter Wiese at Global Life Science Ventures scans the future in his examination of likely funding scenarious for 2006 - ebr Bio-Finance and Management spring 2006 - Early-Late Companies: The New Sweet Spor For European Biotech Venture Capitalists? - EVCJ April 2006
- State of Industry Discussed at BIO-Europe - GEN BioBusiness 15. January 2006.
- An Opportunity to Invest in Europe - business guide to Switzerland 1/2006.
- Many companies have products in Phase II or Phase III - Dr. Hans A. Küpper, Partner & Hanns-Peter Wiese, Partner, Global Life Science Ventures - Biotechnologies & Finances, December 2005 (page 8)
- Dr. Peter Reinisch's presentation, featuring the results of GLSV Biotech Investment Barometer at the 2005 Biotech in Europe Investor Forum.
- Global Life Science Ventures has achived a sound track record through discerning investments in high potential companies - EVCJ Sept 2005.
- Biotechnology in Europe: Turning the Corner . EVCJ Sept. 2005.
- Interview mit Dr. Hans Küpper und Hans-Peter Wiese im Going Public Magazin, Sonderausgabe "Biotechnologie 2005" im September 2005. "Biotechunternehmen scheinen zunehmend der Antrieb für das Wachstum in der Biopharmabranche zu sein.
- Interview mit Dr. Peter Reinisch in Families in Business Sept/Oct 2005, The Science of Biotechnology/Investing.
- Business Guide to Switzerland "Entrepreneurship is Alive and Well in Switzerland
- Hans Küpper discusses science and venture capital - Drugsdiscoverytoday.com, Nov. 2004